Xencor, Inc Payments for (Proceeds from) Loans Receivable
Xencor, Inc (XNCR) reported Payments for (Proceeds from) Loans Receivable of -$86.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromLoansReceivable · last filed 2021-02-24
- Xencor, Inc payments for (proceeds from) loans receivable for the quarter ending 2018-12-31 was $0.00.
- Xencor, Inc payments for (proceeds from) loans receivable for the quarter ending 2018-09-30 was $0.00.
- Xencor, Inc payments for (proceeds from) loans receivable for the quarter ending 2018-06-30 was $0.00.
- Xencor, Inc payments for (proceeds from) loans receivable for the quarter ending 2018-03-31 was -$86.00K, a 149.43% decline year-over-year.
- Xencor, Inc payments for (proceeds from) loans receivable for fiscal 2018 was -$86.00K, a 200.00% decline from fiscal 2017.
- Xencor, Inc payments for (proceeds from) loans receivable for fiscal 2017 was $86.00K, a 86.15% decline from fiscal 2016.
- Xencor, Inc payments for (proceeds from) loans receivable for fiscal 2016 was $621.00K.
| Period end | Payments for (Proceeds from) Loans Receivable 3 month | Payments for (Proceeds from) Loans Receivable 6 month | Payments for (Proceeds from) Loans Receivable 9 month | Payments for (Proceeds from) Loans Receivable 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $0.00 derived: sum of 3 quarters · filed 2021-02-24 | -$86.00K 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | -$86.00K 10-Q · filed 2019-11-05 | -$86.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$86.00K 10-Q · filed 2019-08-07 | -$86.00K derived: sum of 3 quarters · filed 2020-02-25 | -$86.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | -$86.00K 10-Q · filed 2019-05-09 | -$86.00K derived: sum of 2 quarters · filed 2020-02-25 | -$86.00K derived: sum of 3 quarters · filed 2020-02-25 | -$174.00K derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | -$88.00K derived: sum of 3 quarters · filed 2020-02-25 | $86.00K 10-K · filed 2020-02-25 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$88.00K derived: sum of 2 quarters · filed 2018-11-05 | $86.00K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $86.00K 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $174.00K 10-Q · filed 2018-05-07 | |||
| 2016-12-31 | $621.00K 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |